These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 20424113)

  • 21. Disulfiram/copper markedly induced myeloma cell apoptosis through activation of JNK and intrinsic and extrinsic apoptosis pathways.
    Xu Y; Zhou Q; Feng X; Dai Y; Jiang Y; Jiang W; Liu X; Xing X; Wang Y; Ni Y; Zheng C
    Biomed Pharmacother; 2020 Jun; 126():110048. PubMed ID: 32145587
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
    Stemke-Hale K; Gonzalez-Angulo AM; Lluch A; Neve RM; Kuo WL; Davies M; Carey M; Hu Z; Guan Y; Sahin A; Symmans WF; Pusztai L; Nolden LK; Horlings H; Berns K; Hung MC; van de Vijver MJ; Valero V; Gray JW; Bernards R; Mills GB; Hennessy BT
    Cancer Res; 2008 Aug; 68(15):6084-91. PubMed ID: 18676830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation.
    Liu S; Tang Y; Yan M; Jiang W
    Invest New Drugs; 2018 Oct; 36(5):763-772. PubMed ID: 29504069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors.
    Dunn S; Eberlein C; Yu J; Gris-Oliver A; Ong SH; Yelland U; Cureton N; Staniszewska A; McEwen R; Fox M; Pilling J; Hopcroft P; Coker EA; Jaaks P; Garnett MJ; Isherwood B; Serra V; Davies BR; Barry ST; Lynch JT; Yusa K
    Oncogene; 2022 Nov; 41(46):5046-5060. PubMed ID: 36241868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.
    Bonelli MA; Cavazzoni A; Saccani F; Alfieri RR; Quaini F; La Monica S; Galetti M; Cretella D; Caffarra C; Madeddu D; Frati C; Lagrasta CA; Falco A; Rossetti P; Fumarola C; Tiseo M; Petronini PG; Ardizzoni A
    Mol Cancer Ther; 2015 Aug; 14(8):1916-27. PubMed ID: 26013318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.
    Tanaka H; Yoshida M; Tanimura H; Fujii T; Sakata K; Tachibana Y; Ohwada J; Ebiike H; Kuramoto S; Morita K; Yoshimura Y; Yamazaki T; Ishii N; Kondoh O; Aoki Y
    Clin Cancer Res; 2011 May; 17(10):3272-81. PubMed ID: 21558396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PTEN sensitizes MDA-MB-468 cells to inhibition of MEK/Erk signaling for the blockade of cell proliferation.
    Jang K; Kim M; Seo HS; Shin I
    Oncol Rep; 2010 Sep; 24(3):787-93. PubMed ID: 20664988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
    Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
    Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin.
    Liu D; Hou P; Liu Z; Wu G; Xing M
    Cancer Res; 2009 Sep; 69(18):7311-9. PubMed ID: 19706758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PIK3CA mutations-mediated downregulation of circLHFPL2 inhibits colorectal cancer progression via upregulating PTEN.
    Chong X; Chen J; Zheng N; Zhou Z; Hai Y; Chen S; Zhang Y; Yu Q; Yu S; Chen Z; Bao W; Quan M; Chen ZS; Zhan Y; Gao Y
    Mol Cancer; 2022 May; 21(1):118. PubMed ID: 35619132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
    Young CD; Pfefferle AD; Owens P; Kuba MG; Rexer BN; Balko JM; Sánchez V; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
    Cancer Res; 2013 Jul; 73(13):4075-85. PubMed ID: 23633485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy.
    Yu K; Toral-Barza L; Shi C; Zhang WG; Zask A
    Cancer Biol Ther; 2008 Feb; 7(2):307-15. PubMed ID: 18059185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
    Hoeflich KP; O'Brien C; Boyd Z; Cavet G; Guerrero S; Jung K; Januario T; Savage H; Punnoose E; Truong T; Zhou W; Berry L; Murray L; Amler L; Belvin M; Friedman LS; Lackner MR
    Clin Cancer Res; 2009 Jul; 15(14):4649-64. PubMed ID: 19567590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA.
    Kong D; Yamori T; Yamazaki K; Dan S
    Invest New Drugs; 2014 Dec; 32(6):1134-43. PubMed ID: 25152245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MicroRNA-130b targets PTEN to mediate drug resistance and proliferation of breast cancer cells via the PI3K/Akt signaling pathway.
    Miao Y; Zheng W; Li N; Su Z; Zhao L; Zhou H; Jia L
    Sci Rep; 2017 Feb; 7():41942. PubMed ID: 28165066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer.
    Young CD; Zimmerman LJ; Hoshino D; Formisano L; Hanker AB; Gatza ML; Morrison MM; Moore PD; Whitwell CA; Dave B; Stricker T; Bhola NE; Silva GO; Patel P; Brantley-Sieders DM; Levin M; Horiates M; Palma NA; Wang K; Stephens PJ; Perou CM; Weaver AM; O'Shaughnessy JA; Chang JC; Park BH; Liebler DC; Cook RS; Arteaga CL
    Mol Cell Proteomics; 2015 Jul; 14(7):1959-76. PubMed ID: 25953087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of the CK-MB-1 trastuzumab-resistant HER2-positive breast cancer cell line and xenograft animal models.
    Chung WP; Huang WL; Liao WA; Huang WL; Liu YY; Su WC
    Cancer Med; 2021 Apr; 10(7):2370-2379. PubMed ID: 33665980
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.
    Vora SR; Juric D; Kim N; Mino-Kenudson M; Huynh T; Costa C; Lockerman EL; Pollack SF; Liu M; Li X; Lehar J; Wiesmann M; Wartmann M; Chen Y; Cao ZA; Pinzon-Ortiz M; Kim S; Schlegel R; Huang A; Engelman JA
    Cancer Cell; 2014 Jul; 26(1):136-49. PubMed ID: 25002028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor effects of disulfiram/copper complex in the poorly-differentiated nasopharyngeal carcinoma cells via activating ClC-3 chloride channel.
    Xu X; Xu J; Zhao C; Hou X; Li M; Wang L; Chen L; Chen Y; Zhu L; Yang H
    Biomed Pharmacother; 2019 Dec; 120():109529. PubMed ID: 31606620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suppressing autophagy enhances disulfiram/copper-induced apoptosis in non-small cell lung cancer.
    Wu X; Xue X; Wang L; Wang W; Han J; Sun X; Zhang H; Liu Y; Che X; Yang J; Wu C
    Eur J Pharmacol; 2018 May; 827():1-12. PubMed ID: 29547841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.